Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Myelosuppression × Clear all

Phase

Status

Recruiting 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 1630 Neoplasms 1371 Carcinoma, Non-Small-Cell Lung 950 Prostatic Neoplasms 876 Colorectal Neoplasms 794 Lung Neoplasms 723 Pancreatic Neoplasms 534 Carcinoma, Hepatocellular 491 Leukemia, Myeloid, Acute 482 Stomach Neoplasms 462 Ovarian Neoplasms 460 Neoplasm Metastasis 438 Multiple Myeloma 437 Recurrence 369 Melanoma 358 Uterine Cervical Neoplasms 333 Squamous Cell Carcinoma of Head and Neck 329 Head and Neck Neoplasms 325 Brain Neoplasms 318 Esophageal Neoplasms 302 Lymphoma 294 Precursor Cell Lymphoblastic Leukemia-Lymphoma 285 Endometrial Neoplasms 282 Triple Negative Breast Neoplasms 266 Rectal Neoplasms 261 Glioblastoma 259 Urinary Bladder Neoplasms 253 Sarcoma 241 Hematologic Neoplasms 238 Carcinoma, Renal Cell 236

Interventions

trilaciclib 1 Chemoradiotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06490081 2024-09-24

Trilaciclib Prevents Myelosuppression With Chemoradiotherapy

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Myelosuppression

Data powered by HemOnc (CC BY 4.0) Colophon ⚡